Boehringer Ingelheim’s pimobendan
Company is seeking outlicensing agreement or development partnership for the oral positive inotropic drug treatment for congestive heart failure. Decision is based on the "considerable resources" needed to develop drugs in this class to meet U.S. approval requirements, which "would have conflicted" with other "priority projects" in its pipeline, company explains in a March 9 announcement. If no agreement is reached, B-I will halt development of the drug, which is in Phase III.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth